Spondyloarthritis & psoriatic arthritis
Management of Axial Disease in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Treatment Recommendations
Study context
- Population
- Patients with PsA with axial disease (axial PsA (axPsA))
- Outcome
- Efficacy of therapeutic interventions for treatment of axial disease in PsA
Methodological detailsupdate of the axPsA domain of the GRAPPA treatment recommendations project
- Update of the axPsA domain of the GRAPPA treatment recommendations project
Pooled result
As reported in the abstract
- New bDMARD and tsDMARD classes, IL-17A and JAK inhibitors, could be considered for treatment of axPsA
- In addition to previously recommended NSAIDs, physiotherapy, simple analgesia and TNFi
- Conflicting evidence remains regarding IL-12/23 and IL-23 inhibitors
Original publication
Management of Axial Disease in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations. J Rheumatol. Published 1 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →